Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCARH109
- Development stage
- Phase 3
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MCARH109 is a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor (CAR) T-cell therapy. It is used for treating relapsed/refractory multiple myeloma. The therapy involves autologous T lymphocytes transduced with a retroviral vector expressing a CAR. It works by inducing immunologic cytotoxicity and replacing T lymphocytes.
- Other names
- Anti-GPRC5D CAR T cell therapyAnti-GPRC-5D CAR T cell therapyAnti-GPRC 5D CAR T cell therapyGPRC5D Targeted MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells
02
Targets
GPRC5D
Beyond the preview
Go deeper on MCARH109.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCARH109.